Furthermore, novel strategies involving IL-6 inhibition in EGFR-mutant NSCLC with acquired EGFR-TKI resistance point to potential synergic effects between targeted therapies and immunomodulation. This evidence concerns the gene IL6 and non-small cell lung carcinoma.